Follow us...

 

Search News Archives

News Channels

 

New Laboratory Products

Lab News

What's going on at Lab Innovations

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

Organizations Join Forces to Create Global Alliance Against Antibiotic Resistance

publication date: May 15, 2019
 | 
author/source: UMC Utrecht

UMC UtrechtThe U.S.-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.

This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences like the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and IDWeek, cross-entity working groups with diverse functional group participation, clinical trial innovations, data and protocol exchanges, and, contractual, regulatory, and systems harmonization.

“We at the ARLG have long admired the work being done by COMBACTE to increase the efficacy of antimicrobial drug development,” said Vance Fowler, MD, an investigator at the DCRI and co-principal investigator of the ARLG. “Combining our efforts will allow us to maximize the work we both do to stop the advancement of antibacterial resistance.”

Both organizations have been working toward the same mission since each launched in 2013, and now, the two groups will share their work to increase synergy and avoid duplicative efforts in clinical research.

“We have already made efforts to expand our reach across Europe, where an increasing number of people suffer from infections caused by antibiotic-resistant bacteria,” said Marc Bonten, MD, coordinator of COMBACTE and a professor at UMC Utrecht. “But by collaborating and sharing our progress with the ARLG, we can make a truly global impact beyond this population — an important consideration in a globally connected era in which epidemics travel across oceans quickly.”

As part of the agreement, the ARLG will have the opportunity to lead and coordinate U.S.-based studies for all clinical research initiated by COMBACTE, while COMBACTE will have the opportunity to lead and coordinate ARLG-initiated projects in Europe.

Earlier this year the European Clinical Research Alliance on Infectious Diseases (ECRAID) was formed, merging COMBACTE’s more than 850 clinical trial sites and 650 laboratories with the network of primary care sites coordinated by The Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) to form a European-wide sustainable clinical research organization for infectious diseases and antimicrobial resistance. The ARLG, with established collaborations in 19 countries, will help to expand these efforts outside of Europe. The alliance will enable innovative, flexible, and adaptive collaboration between the DCRI and UMC Utrecht.

“This is an exciting year for PREPARE to expand its work in reducing a serious public health threat,” said Herman Goossens, MD, coordinator of PREPARE and professor at University of Antwerp and UMC Utrecht. “First, we joined forces with COMBACTE by forming ECRAID, and now, we welcome a partnership with the ARLG, which will help all three organizations leverage a wider set of resources and a deeper pool of expertise.”

The ARLG is supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number UM1AI104681. COMBACTE-NET, COMBACTE-CARE, and COMBACTE-MAGNET receive support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. COMBACTE-CDI receives support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement n° 777362 resources of which are composed of financial contribution from the European Union’s Horizon 2020 research and innovation programme, and EFPIA. PREPARE is funded by the European Union’s FP7 Programme n° 602525. ECRAID is funded by the European Union’s Horizon 2020 Programme n° 825715.

 

find out more




 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners